Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Q3 2022 Halozyme Therapeutics Inc Earnings Call Transcript

Nov 08, 2022 / 09:30PM GMT
Release Date Price: €46.08 (-1.30%)
Operator

Good afternoon. My name is Chantel, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Third Quarter 2022 Financial and Operating Results Conference Call. (Operator Instructions) Please note, this event is being recorded.

I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.

Tram Bui
Halozyme Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, operator. Good afternoon, and welcome to our third quarter 2022 financial and operating results conference call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, who will review our financial results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot